|
|
Title: Bioactive spinal implant
material and method of manufacture thereof
United States Patent: 6,987,136
Issued: January 17, 2006
Inventors: Erbe; Erik M. (Berwyn, PA);
Murphy; James P. (Broomall, PA); Pomrink; Gregory J. (Lansdale, PA)
Assignee: Vita Special Purpose Corporation
(Wilmington, DE)
Appl. No.: 127947
Filed: April 23, 2002
|
|
|
Executive MBA in Pharmaceutical Management, U. Colorado
|
Abstract
Bioactive spinal implant materials having
optimized radiopacity, stiffness, and bioactivity properties for
formulation of shaped bodies capable of withstanding large dynamic,
compressive loads are provided. The invention also provides methods of
making the optimized implant materials.
SUMMARY OF THE
INVENTION
The present invention provides synthetic
spinal implant materials that have a radiopacity similar to bone for
facilitating radiographic assessment of fusion. The implant materials of
the present invention are capable of withstanding physiologic dynamic,
compressive loads and is bioactive and biocompatible. As defined herein,
bioactive relates to the chemical formation of a calcium phosphate layer
via ion exchange between surrounding fluid and the implant materials.
Bioactive can also relate to materials that elicits a reaction which leads
to bone formation or attachment into or adjacent to implants or to bone
formation or apposition directly to the implants usually without
intervening fibrous tissue. Biocompatible as defined herein relates to
materials that do not invoke a prolonged adverse immunologic or host
response. The present invention also provides methods for making such
implant materials.
In certain embodiments of the present invention, the implant materials of
the present invention can be comprised of a biocompatible polymeric matrix
reinforced or coated with bioactive fillers and fibers. The implants can
probably be comprised of a diurethane dimethacrylate (DUDMA) and
tri-ethylene glycol dimethacrylate (TEGDMA) blended resin and a plurality
of fillers and fibers including bioactive fillers and E-glass fibers. The
implants may also be comprised of a variety of other monomers and fillers
as described herein.
This invention teaches synthetic, bioactive spinal implant materials
having a range of radiopacity from about 30 to about 55 and a range of
stiffness from about 6 GPa to about 20 GPa. The invention also provides a
synthetic, artificial shaped bodies in the form of a spinal implant, said
implant shaped body having a radiopacity of about 30 to about 55 and a
range of stiffness of about 6 GPa to about 20 GPa. Another embodiment
discloses synthetic spinal implant materials that are optimized for
radiopacity, stiffness, and bioactivity, comprising: a polymerizable resin
matrix of DUDMA and TEGDMA resins and at least one filler.
The implant materials can be formed from a polymerized resin matrix and
can include at least one filler that can be bioactive. A bioactive filler
can comprise combeite. The polymerized matrix can comprise about 20% to
about 50% of the total composition of the implant material. Fifty to about
80% of the filler can comprise the total composition of the implant
material. The radiopacity of the implants can range from about 38 to about
50. Also, the stiffness can range from about 8 GPa to about 17 GPa.
Also included are methods of making a synthetic spinal implant material
that is optimized for radiopacity, stiffness and bioactivity comprising:
mixing a resin blend of DUDMA and TEGDMA mixing said resin blend with at
least one filler, and agitating the to form said implant material.
The embodiment of this invention can be used to form a variety of
different orthopaedic implants, particularly spinal implants having
various shapes and sizes.
The present invention provides bioactive and biocompatible implant
materials for formulation of shaped bodies capable of withstanding large
dynamic, compressive loads, especially spinal implants. Further, the
implant materials of the present invention overcome the risks associated
with disease transmission present with allograft devices. Moreover, the
implant materials of the present invention exhibit a radiopacity similar
to that of bone.
The materials of this invention are preferably comprised of a
biocompatible, hardenable polymeric matrix reinforced with bioactive and
non-bioactive fillers. The materials can be comprised of about 10% to
about 90% by weight of the polymeric matrix and about 10% to about 90% by
weight of one or more fillers. The materials can also be comprised of
about 20% to about 50% by weight of the polymeric matrix and about 50% to
about 80% by weight of one or more fillers. In order to promote bone
bonding to the implants, the implants of the present invention can be
comprised of a bioactive material that can comprise a polymeric blended
resin reinforced with bioactive ceramic fillers. Examples of such
bioactive materials can be found, for example, in U.S. Pat. Nos. 5,681,872
and 5,914,356 and pending application U.S. Ser. No. 60/305,070, which is
assigned to the assignee of the present invention and incorporated herein
by reference in its entirety.
The polymeric matrixes of the implant materials are comprised of
polymerizable monomer, monomers, dimers or trimers. They can comprise
ethylenically unsaturated monomers or even an acrylate functional group.
The term "monomers," as used herein, can also represent dimers, trimers,
resins, resin components or any other polymerizable component. Examples of
the monomers include, but are not limited to, DUDMA, bisphenol-A-glycidyl
methacrylate (bis GMA), TEGDMA, ethoxylated bisphenol-A-dimethacrylate (bis-EMA),
or combinations thereof. Still, further examples of monomers that can be
used in the present invention include the adducts of 2,2,3-trimethylhexane
diisocyanate with hydroxyethyl methacrylate, hydroxypropyl methacrylate,
and other hydroxyacrylic acrylic species can also be used. Other examples
of polymerizable species that can be used in the present invention include
those disclosed in U.S. Pat. Nos. 5,681,872 and 5,914,356, and pending
application U.S. Ser. No. 60/305,070, which are incorporated herein by
reference in their entirety.
Methyl methacrylate, ethyl methacrylate, propyl methacrylate, higher
methacrylates, acrylates, ethacrylates, and similar species can be
employed as all or part of the polymerizable materials of the implant
materials of the present invention. It is also possible to employ other
types of polymerizable material such as epoxide compounds,
polyurethane-precursor species and a wide host of other materials. For
example, other monomers useful in the production of hardenable
compositions of this invention include methyl-, ethyl, isopropyl-,
tert-butyloctyl-, dodecyl-, cyclohexyl-, chloromethyl-, tetrachloroethyl-,
perfluorooctyl-, hydroxyethyl-, hydroxypropyl-, hydroxybutyl-,
3-hydroxyphenyl-, 4-hydroxphenyl-, aminoethyl-, aminophenyl-, thiophenyl-,
acrylate, methacrylate, ethacrylate, propacrylate, butacrylate, and
chloromethacrylate, as well as the homologous mono-acrylic acid esters of
bisphenol-A, dihydroxydiphenyl sulfone, dihydroxydiphenyl ether,
dihydroxybiphenyl, dihydroxydiphenyl sulfoxide, and 2,2
bis(4-hydroxy-2,3,5,6-tetrafluorophenyl)propane. Polymerizable monomers
capable of sustaining a polymerization reaction such as the di-, tri-, and
higher acrylic ethylene glycol dimethacrylate, diethylene glycol
dimethacrylate, trimethylene glycol dimethacrylate, trimethylol propane
trimethacrylate, analogous acrylates and similar species are also useful.
It is also possible to employ mixtures of more than two polymerizable
species to good effect.
The implant materials of the present invention can further comprise
polymeric additives that include, but are not limited to, polymerization
inhibitors, polymerization activators, polymerization initiators,
stabilizers such as UV-9, radiopacifiers, reinforcing components (i.e.,
fibers, particles, micro spheres, flakes, etc.), bioactive fillers,
neutralizing resins, diluting resins, antibiotic agents, coloring agents,
plasticizers, coupling agents, free radical generators, radiographic
contrast agents, and antibiotics.
In many embodiments, the implant materials include a monomeric blended
resin of DUDMA to impart strength, TEDGMA to impart flexibility, a benzoyl
peroxide initiator (BPO) or any peroxide initiator that is consumed during
the polymerization reaction, and at least one polymer stabilizer. The
implant materials can also include a plurality of fillers and fibers. The
fillers can be of the combeite type, such as the combeite filler described
in U.S. Pat. No. 5,681,872 to render the material bioactive and encourage
direct bone bonding. Alternatively, the filler can be selected from a
group of fillers including, but not limited to, borosilicate, silica,
Wollastonite, hydroxyapatite (HA), beta-tricalcium phosphate, calcium
sulfate, alumina, and the like. In embodiments where the implants further
comprise fibers, the fibers can further include E-glass fibers of the
composition type [SiO2 CaO Al2O3 B2O3,
A-glass fibers, silica or a plurality of other fibers including but not
limited to Kevlar and carbon fibers for imparting toughness and strength
to the implant. In certain embodiments, the fillers and fibers are surface
treated for incorporation and bonding between them and the resin. For
example, the fillers and fibers can be silanated, silicone-oil treated, or
provided with coupling agents such alumina, titania, or zirconia coupling
agents.
Certain embodiments have optimized radiopacity and stiffness and display
bioactivity. As defined herein and in ASTM standards, radiopacity is
calculated as an optical density ratio of the material versus an aluminum
standard of the same thickness, both of which are normalized by the
background sample optical density. The resultant number is multiplied by
100 and then referred to as the percent relative linear attenuation
coefficient, α, which is dimensionless. Embodiments of the present
invention are synthetic, bioactive spinal implant materials having a
radiopacity between about 30 to about 55 and stiffness between about 6 GPa
to about 20 GPa. Other embodiments provide a synthetic, artificial shaped
body in the form of a spinal implant, said shaped body having a
radiopacity of about 30 to about 55 and a stiffness of about 6 GPa to
about 20 GPa.
The radiopacity of bone ranges between about 24 to about 52 as reported by
Brantigan, et al., "Compression Strength of Donor Bone for Posterior
Interbody Fusion," Spine, 18, 1213-1221 (1983), with a stiffness
ranging from about 3 GPa to about 17 GPa. Similar to bone, which is
naturally bioactive, the present inventions also display bioactivity.
In other embodiments, the spinal implant materials can have a radiopacity
of about 30 to 55 and a range of stiffness of about 8 GPa to 17 GPa. The
spinal implant can be formed from a polymerized resin matrix. At least one
filler can be included in other embodiments and any of the fillers can be
bioactive. The bioactive filler can be combeite glass ceramic or another
type of ceramic filler. In some embodiments, the polymerized resin matrix
comprises about 20% to about 50% of the total composition of the implant
material. About 50% to about 80% of the total composition of the implant
material can be filler.
Certain embodiments are synthetic spinal implant materials that are
optimized for radiopacity, stiffness, and bioactivity, comprising a
polymerizable resin matrix of DUDMA and TEGDMA resins and at least one
filler.
While the present invention material has been described in terms of
polymeric matrices comprised of polymerizable monomers and the like, it
should be understood that the disclosed radiopacity and stiffness ranges
may be achieved by using a variety of materials. For instance, the
polymeric matrix may be composed of any polymeric material and include an
additional organic or inorganic component. The matrix may be
thermoplastic, thermoset, polymerizable, or non-polymerizable. Epoxies,
polyurethanes, polyphosphates, polyesters, polyamides, polyphosphazenes,
polycarbonates, polyureas, polyamides, polyacrylonitriles, polysulfones,
polysulfides, polysiloxanes, polyacetals, polyethers such as
polyetheretherketone (PEEK), fluoropolymers, polyketals, polyolefins such
as polyethylene (PE), polypropylene (PP), polystyrene, and
polyvinylchloride (PVC), and the like may also be used. These materials
may be used either alone, in combination, or with various fillers to form
a copolymer or terpolymer with the present invention to provide an implant
material that yields desired radiopacity and stiffness comparable to bone
as described herein.
Also included as a part of the present invention are methods of making a
synthetic implant material that is optimized for radiopacity, stiffness,
and bioactivity, comprising mixing a resin blend of DUDMA, TEGDMA, and a
stabilizer, mixing said resin blend with at least one filler, and
agitating the resultant mixture to form said implant material. The resin
blend can also comprise an initiator. Both mixing steps can occur under
vacuum. The fillers can be added in the range of about 15% by weight to
about 80% by weight of the total mixture composition. If vacuum is applied
at this stage, it can be applied upon the addition of each filler.
Agitation of the resultant mixture can be added to further eliminate
bubbles or voids.
In one embodiment of the present invention, the monomers, fillers, and
other additives are blended together to form a paste composition. The
paste compositions are easily mixed via a low speed, high shear rotary
mixer. The duration of the blending operation will vary depending upon the
constituents that comprise the paste composition precursors. In one
embodiment, the blending of the monomers and other additives within the
paste composition precursors activates the polymerization of the
composition. In another embodiment, exposure to heat either during or
after blending activates the polymerization. The exposure can occur in
temperature ranges of about 40° C. to about 180° C. or about 60° C. to
about 120° C. in some instances.
The implant materials of the present invention can be comprised of a one
paste system or combined with two or more paste compositions to form a
multiple paste system. Depending upon whether the implant material is a
one paste or multiple paste system determines the hardening of the
material. The paste compositions of the present invention can be hardened
under the influence of heat, photochemical energy, chemically, or in a
controlled fashion. In certain embodiments wherein the implant materials
comprise a one paste system, the paste composition is hardened or cured
via exposure to heat or light. Alternatively, the paste composition could
be cured via gamma radiation. In some embodiments, additional exposure to
gamma radiation can impart additional strength. In other embodiments
wherein the implant materials comprise a multiple paste system, the paste
compositions are admixed and hardened via thermal energy or heat cured.
The paste compositions can also be chemically cured via catalyst or redox
systems. It will be understood, however, that a wide variety of
polymerization systems and materials for use therein can be employed to
good advantage in connection with the present invention and all such
systems are contemplated hereby. Depending upon the system that is
employed, the paste composition can generally comprise heat-curing
catalysts, photopolymerization, or redox (i.e.
N,N(dihydroxyethyl)-p-toluidine(DHEPT), BPO, FeII, tertiary butyl
hydroperoxide (t-BHP)) initiators. Each type is well-known and any
catalytic system known for restorative use can be employed so long as the
same is consistent with the objects of the invention.
In multiple paste systems where heat curing is used to harden the
composition, a catalytic system is employed such that when two components
of the hardenable composition are mixed together, the catalytic action
begins, leading to hardening. This system is familiar and can be applied
to a wide variety of polymerizable species including many which are
suitable in the present invention. Radical initiators such as peroxides,
especially benzoyl peroxide (also called dibenzoyl peroxide) are
conventional, economic and convenient. A stabilizer such as butyl hydroxy
toluene is customary, as is employment of co-catalysts like
dimethyl-p-toluidine, N-N-substituted toluidine, and other conventional
catalysts including tertiary amine structures with double bond
functionality like diethyl aminoethyl methacrylate and
N,N-dimethyl-p-toluidine. In general, one of the pastes incorporates both
the radical initiator and stabilizer, such as a peroxide, and the other
paste incorporates the accelerator, such as an amine or toluidine. Curing
is initiated by an oxidation-reduction mechanism upon mixing the two
pastes together.
In paste systems where curing via exposure to heat or other means is used
to harden the composition, a photoinitiation system can be included with
the hardenable compositions and the same caused to be activated by
exposure to actinic light of a suitable wavelength. Both ultraviolet and
visible photocuring systems are known for use in restorative surgery and
dentistry and any such system can be employed herein. Exemplary systems
are described in U.S. Pat. No. 4,110,184 to Dart et al., U.S. Pat. No.
4,698,373 to Tateosian et al., U.S. Pat. No. 4,491,453 to Koblitz et al.,
and U.S. Pat. No. 4,801,528 to Bennett, which are incorporated herein by
reference in their entirety to provide enablement for such, known systems.
A particularly useful system employs visible light curing, thus avoiding
the potential danger inherent in curing with ultraviolet radiation.
Visible light curing has been well refined in the dental field and the
same can also be applied to restorations of bony tissues. Quinones, as a
class, find wide utility as photochemical initiators for visible light
sensitizing systems, preferably when the same are admixed with tertiary
amines. Some skilled artisans may prefer that an alpha diketone (quinone)
such as camphoroquinone or biacetyl be admixed with an amine reducing
agent such as n-alkyl dialkanolamine or trialkanolamine. Other such
photo-initiator systems include a 2-Benzyl-2-(dimethylamino)-4′-morpholinobutyrophenone,
or 50%/50% weight composition of
2-Hydroxyethyl-2-methyl-1-phenyl-1-propanone and Diphenyl
(2,4,6-trimethylbenzyl) phosphine oxide. However, other such curing
systems or combinations of curing systems can also be employed with the
materials of the present invention.
In some embodiments, the paste system is not cured or hardened but used in
situations in which the paste form is preferred. In those cases, the paste
may be dispensed from a tube or the like. In other embodiments, one or
more fillers are blended into the paste composition after the monomers and
other additives comprising the resin blend have been combined. The fillers
can be added incrementally to avoid binding during the blending process. A
vacuum can be applied during blending to minimize porosity and dusting.
Some embodiments comprise multiple fillers, which may include E-glass
fibers and fillers or fibers of borosilicate, silica, and combeite. In
particular embodiments, the E-glass fibers can be added first followed by
the remaining fillers in a designated order. Alternatively, one or more
fillers can be pre-blended together prior to incorporation into the resin
blend. After the filler has been combined with the resin mixture, the
completed paste mixture can be agitated via a vibrating table, ultrasonic
or similar means for a period of time ranging from about 5 minutes to
about 60 minutes to further reduce porosity. A vacuum can be applied
during the agitation step.
Table I shows a number of compositions in accordance with certain
preferred embodiments of the present invention together with salient data
showing suitability for orthopaedic, especially spine implant use. Six
exemplary implant materials were made in accordance with the present
invention. The weight percentage of each composition is presented in the
table. As the following table illustrates, the Examples 2-4 are multiple
paste systems wherein Examples 5-7 are one paste systems.
The implant materials of Examples 2-7 can be fashioned into standard
shapes, which include cylinders, bricks, and dog bones, for testing. Along
with radiopacity, the compressive strength, compressive yield, and
compressive modulus were tested, as were the tensile strength and tensile
modulus. Compressive testing was conducted in accordance with ASTM D
695-91 using 6 mm diameter×12 mm height cylindrical specimens. Tensile
testing was conducted in accordance with ASTM D 638-95, using Type IV
specimen geometry of flat tensile bars or "dog bone". Lastly, radiopacity
was conducted in accordance with ASTM F 640-79 ("Radiopacity of Plastics
for Medical Use").
| |
Ex. 2 |
Ex. 3 |
Ex. 4 |
Ex. 5 |
Ex. 6 |
Ex. 7 |
| |
|
| Formulation Comparison |
|
|
|
|
|
|
| [Product (%)] |
| Bis-GMA |
12-14 |
13-15 |
0-1 |
0-1 |
0-1 |
0-1 |
| Bis-EMA |
5-7 |
6-8 |
0-1 |
0-1 |
0-1 |
0-1 |
| TEGDMA |
11-13 |
12-14 |
8-10 |
7-9 |
7-9 |
7-9 |
| DUDMA |
0-1 |
0-1 |
24-28 |
24-28 |
24-28 |
24-28 |
| t-Butylhydroxytoluene |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
| DHEPT |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
| UV-9 (C14H12O3) |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
| BPO |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
| Silane Treated Amorphous |
7-9 |
6-8 |
6-8 |
4-6 |
4-6 |
4-6 |
| Silica |
| Silane Treated Orthovita |
28-31 |
18-21 |
18-21 |
20-23 |
22-24 |
19-21 |
| Combeite [OC] Filler |
| Silane Treated |
| Bariaboroaluminosilicate |
29-32 |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
| Glass |
| Silane Treated Alkali Leached |
0-1 |
16-19 |
16-19 |
20-23 |
19-21 |
0-1 |
| OC Filler |
| Silane Treated E-Glass |
0-1 |
19-21 |
19-21 |
19-21 |
19-21 |
19-21 |
| Silane Treated Borosilicate |
0-1 |
0-1 |
0-1 |
0-1 |
0-1 |
22-24 |
| Filler |
| Approx. Test Parameter |
| before Gamma Irradiation |
| Compressive Strength (MPa) |
211 |
— |
— |
195.6 |
216.3 |
238.4 |
| Compressive Yield (MPa) |
127 |
105 |
125 |
150 |
170 |
182 |
| Compressive Modulus (MPa) |
5800 |
6998 |
7875 |
8456 |
8403 |
8516 |
| Tensile Strength (MPa) |
52.5 |
60.2 |
54.3 |
— |
63.4 |
86.7 |
| Tensile Modulus (MPa) |
9800 |
10306 |
11976 |
— |
14839 |
16290 |
| Radiopacity |
118.6 |
— |
50 |
— |
46.3 |
57.3 |
| |
Although the uses described above are
exemplary for the present invention, there are other embodiments that may
be foreseen by those skilled in the art. Within the dental field, the
implants of the present invention can have use as dental crowns (temporary
or crown) and dental implants, including Maryland bridges. The implant
materials can also have use as implants for other areas of the animal
body. Such foreseeable implants include cochlear, cranial, tumor, sternum,
or other custom implants that can be MRI compatible or functional shapes
made for the body. Other embodiments can be used for formulation of
universal plates for orthopedic use, bone screws, rods, and pins for
orthopedic use (IM nails, femoral rods or plugs, long bone fractures,
etc.), tendon anchors, suture anchors and tacks, graft retainers, and
marrow sampling ports.
Other pharmaceutical uses include non-articulating artificial joint
surfaces, sensor anchors or housings, bone spacers or wedges (tibial,
femoral), cartilage beds or anchors, or drug delivery. It is also
foreseeable that the implant materials can be used in methods for
repairing the iliac harvest site. The materials can be incorporated into
drug delivery beads into bone or in interbody balls. There can also be
applications for mandibular joints (TMJ) and orbital reconstruction.
One embodiment of the present invention involves machining of the
implantable materials into morsels for use in methods to treat segmental
defects. The morsels can also be used for minimally invasive load bearing
applications. The material can be made into a mesh for postero-lateral
fusion or cages for other materials. Other embodiments involve the
material being used as a cannulated screw with peripheral holes used in
methods for treating vertebral augmentation. The present invention can
have embodiments involving synthetic bones.
Claim 1 of 21 Claims
1. An implant comprising a
synthetic, bioactive spinal implant material formed from a one-paste, 0% by
weight bisphenol-A-glycidyl methacrylate polymerized resin matrix comprising
about 10% by weight to about 60% by weight of the total composition of the
implant material, the polymerized resin matrix comprising diurethane
dimethacrylate and tri-ethylene glycol dimethacrylate resins, the resin
matrix further comprising silane treated borosilicate filler, the implant
material having a range of radiopacity from about 30 to about 55 and a range
of stiffness from about 6 GPa to about 20 GPa.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|